Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today's Bonus Article
Intuitive Surgical's Selloff Sets Up a 30% Rebound OpportunityAuthor: Thomas Hughes. Published: 4/23/2026. 
Key Points
- Instuitive Surgical hit bottom in early 2026 and is set up to rebound robustly.
- Accelerting device placement, procedure volume, and consumable supplies underpin the growth outlook.
- Competition exists but trails significantly, leaving this company with a wide moat.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
Intuitive Surgical’s (NASDAQ: ISRG) primary headwinds are its high valuation and slowing growth. That combination has weighed on price action since early 2025 and is unlikely to disappear overnight. However, the current valuation already embeds a solid growth outlook and may still understate the company’s long-term potential. Intuitive Surgical’s potential lies in the dominance of robotic surgical procedures. The company has a first-mover advantage, with an installed base of more than 12,000 devices and counting. In that context, a 45x valuation relative to current-year earnings is only one hurdle, given the potential for a 50% or greater stock-price increase over the next few years.
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
That view assumes long-term forecasts are accurate. As it stands, Intuitive Surgical consistently outperforms expectations, and device deployments and procedure volumes continue to rise. The more likely scenario is that ISRG continues to outpace estimates and drives a bullish revision cycle over the long term. Market Overreaction Sets Up ISRG OpportunityAnalysts contributed to ISRG’s stock price decline in 2026. Leading up to the fiscal Q1 2026 release, the trend was downward price-target revisions, but the market overreacted, creating a deep-value opportunity. That consensus price target implies more than 30% upside from critical support levels, and analyst conviction remains high. MarketBeat tracks 25 analysts, rating the stock a consensus Moderate Buy with a 68% buy-side bias that is echoed in institutional activity. The institutional activity is telling. Institutions own more than 80% of the stock and have been accumulating throughout the corrective period. Their buying accelerated into Q1 2026 and stayed strong in the first weeks of Q2. The trailing 12-month balance is nearly $2-to-$1 in favor of buyers, with Q1 and Q2 flows reflecting accelerating demand. The takeaway: ISRG has a solid floor in the $445–$450 region and is positioned for a robust rebound later in 2026. Stock price action mirrors institutional activity, with declines arrested near $445 and rebounds following. The mid-Q2 setup points to a recovery, as the market showed support at that critical level and advanced after the Q1 release. Indicators such as the MACD and the stochastic oscillator are aligned, suggesting a trend-following move that could take the stock back to record levels. Technical hurdles include the long-term 150-day exponential moving average near $500 and resistance at prior peaks around $560 and $600. Buybacks Add Leverage: Underpin Stock Price OutlookBuybacks are one reason this stock can set new highs. Not only is the company outperforming and forward estimates improving, but buybacks have improved shareholder leverage. The Q1 release shows more than $1.1 billion in quarterly repurchases, enough to reduce the share count by about 0.15% sequentially and roughly 1.3% year over year, with the capacity to continue buying shares at a robust pace. Intuitive Surgical’s balance sheet reflects the impact of buybacks and acquisitions, but those effects are offset by strong cash flow and the shareholder leverage gained. Lower cash balances are balanced by reduced liabilities and relatively stable equity. In this context, ISRG can continue repurchases while maintaining balance-sheet health, including a zero-debt position. As it stands, Intuitive Surgical is net cash relative to total liabilities, with cash more than 3.15 times its liabilities — among the strongest balance sheets on Wall Street. Intuitive Surgical’s Q1 Release Triggers Market ReboundIntuitive Surgical delivered a robust Q1, confirming its underlying trends and suggesting forward estimates may be conservative. Net revenue of $2.77 billion was up 23.1% year over year, outperforming consensus by more than 550 basis points. Growth was driven by device placements (up 17%), procedure volume (up 17%), and instrument sales (up 23%). The installed base grew 12%, pointing to continued gains in coming quarters, and margins improved. Adjusted net income rose 36%, outpacing top-line growth by more than 1,300 basis points, and is expected to remain strong in upcoming quarters. Guidance calls for full-year Da Vinci device growth of roughly 14.5%, with procedures and instrument sales following suit. Aside from valuation, the biggest risk is competition, although rivals are currently trailing. The closest competitor is Medtronic’s (NYSE: MDT) Hugo system, which has seen success overseas but remains in early rollout stages. Key catalysts for ISRG include the early success of the Da Vinci 5, AI-driven opportunities, and international expansion. Japan, in particular, recently approved seven new robotic procedures and is viewed as an important growth driver. |
Tiada ulasan:
Catat Ulasan